NZ754827A - Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases - Google Patents
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseasesInfo
- Publication number
- NZ754827A NZ754827A NZ754827A NZ75482717A NZ754827A NZ 754827 A NZ754827 A NZ 754827A NZ 754827 A NZ754827 A NZ 754827A NZ 75482717 A NZ75482717 A NZ 75482717A NZ 754827 A NZ754827 A NZ 754827A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- compounds
- treatment
- hyperproliferative diseases
- pyrazole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428271P | 2016-11-30 | 2016-11-30 | |
| PCT/US2017/063774 WO2018102453A1 (en) | 2016-11-30 | 2017-11-29 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ754827A true NZ754827A (en) | 2025-10-31 |
Family
ID=62241871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ754827A NZ754827A (en) | 2016-11-30 | 2017-11-29 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11325903B2 (enExample) |
| EP (1) | EP3548482A4 (enExample) |
| JP (1) | JP7373992B2 (enExample) |
| CN (2) | CN118930533A (enExample) |
| AU (1) | AU2017366901B2 (enExample) |
| BR (1) | BR112019011044A2 (enExample) |
| CA (1) | CA3081983A1 (enExample) |
| IL (1) | IL266930B2 (enExample) |
| MX (1) | MX2019006299A (enExample) |
| NZ (1) | NZ754827A (enExample) |
| WO (1) | WO2018102453A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3458445B1 (en) | 2016-05-18 | 2021-02-17 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| BR112019011035A2 (pt) * | 2016-11-30 | 2019-10-15 | Bantam Pharmaceutical Llc | métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2019236966A2 (en) | 2018-06-07 | 2019-12-12 | Bantam Pharmaceutical, Llc | Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| ES3004338T3 (en) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Combination therapies |
| WO2020118066A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| CA3142196A1 (en) | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative |
| EP3976605B1 (en) | 2019-05-31 | 2025-08-20 | Bantam Pharmaceutical, LLC | Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| IL294048A (en) | 2019-12-20 | 2022-08-01 | Mirati Therapeutics Inc | sos1 inhibitors |
| US20230212164A1 (en) * | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| KR20230137286A (ko) | 2020-09-11 | 2023-10-04 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제의 결정 형태 |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
| KR20240128852A (ko) | 2021-12-01 | 2024-08-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
| JP2024543976A (ja) * | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CN116678810A (zh) * | 2022-02-23 | 2023-09-01 | 武汉市鼎华双雄生物科技有限责任公司 | 细胞增殖免疫荧光检测试剂盒及其应用 |
| CN117003651B (zh) * | 2023-09-28 | 2024-01-02 | 广东嘉博制药有限公司 | 一种l-肾上腺素的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1301968B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| ES2208227T3 (es) | 1999-12-03 | 2004-06-16 | Pfizer Products Inc. | Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos. |
| EP1513534A2 (en) | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| US20060194807A1 (en) * | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| JP2006523701A (ja) | 2003-04-18 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール |
| WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| MX2010001462A (es) | 2007-08-27 | 2010-03-01 | Basf Se | Compuestos de pirazol para controlar plagas de invertebrados. |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| CA2722733C (en) | 2008-04-28 | 2016-02-23 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylamide derivative |
| WO2014066304A1 (en) | 2012-10-22 | 2014-05-01 | Egenix, Inc. | Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e |
| CA2943659C (en) * | 2014-03-27 | 2023-04-25 | Merck Patent Gmbh | Pyridyl piperidines |
| WO2016169886A1 (en) | 2015-04-24 | 2016-10-27 | Syngenta Crop Protection Ag | Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles |
| JP6707630B2 (ja) * | 2015-06-01 | 2020-06-10 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法 |
| BR112019011035A2 (pt) * | 2016-11-30 | 2019-10-15 | Bantam Pharmaceutical Llc | métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| CA3142196A1 (en) * | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative |
-
2017
- 2017-11-29 AU AU2017366901A patent/AU2017366901B2/en active Active
- 2017-11-29 CN CN202410345199.5A patent/CN118930533A/zh active Pending
- 2017-11-29 JP JP2019528861A patent/JP7373992B2/ja active Active
- 2017-11-29 CA CA3081983A patent/CA3081983A1/en active Pending
- 2017-11-29 US US16/465,136 patent/US11325903B2/en active Active
- 2017-11-29 IL IL266930A patent/IL266930B2/en unknown
- 2017-11-29 MX MX2019006299A patent/MX2019006299A/es unknown
- 2017-11-29 NZ NZ754827A patent/NZ754827A/en unknown
- 2017-11-29 WO PCT/US2017/063774 patent/WO2018102453A1/en not_active Ceased
- 2017-11-29 CN CN201780084999.4A patent/CN110603254B/zh active Active
- 2017-11-29 BR BR112019011044-5A patent/BR112019011044A2/pt active Search and Examination
- 2017-11-29 EP EP17876486.6A patent/EP3548482A4/en active Pending
-
2022
- 2022-05-10 US US17/741,153 patent/US20230076820A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230076820A1 (en) | 2023-03-09 |
| RU2019120233A3 (enExample) | 2021-03-11 |
| EP3548482A1 (en) | 2019-10-09 |
| US20190345152A1 (en) | 2019-11-14 |
| WO2018102453A1 (en) | 2018-06-07 |
| BR112019011044A2 (pt) | 2019-10-08 |
| IL266930B2 (en) | 2025-09-01 |
| IL266930A (en) | 2019-07-31 |
| JP7373992B2 (ja) | 2023-11-06 |
| MX2019006299A (es) | 2019-11-12 |
| AU2017366901B2 (en) | 2022-09-29 |
| EP3548482A4 (en) | 2020-08-19 |
| IL266930B1 (en) | 2025-05-01 |
| CN110603254B (zh) | 2024-04-12 |
| US11325903B2 (en) | 2022-05-10 |
| CN118930533A (zh) | 2024-11-12 |
| RU2019120233A (ru) | 2021-01-11 |
| CN110603254A (zh) | 2019-12-20 |
| CA3081983A1 (en) | 2018-06-07 |
| JP2019536785A (ja) | 2019-12-19 |
| AU2017366901A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ754827A (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| MX2019006296A (es) | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
| NZ705040A (en) | Fused pyrimidines as inhibitors of p97 complex | |
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| PH12015502615B1 (en) | Chemical compounds | |
| PH12018500605A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2015000129A (es) | Derivados de pirimidin pirazolilo. | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| NZ610526A (en) | Deuterium enriched rasagiline | |
| PH12015501088A1 (en) | Dimeric compounds | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| GB201209587D0 (en) | Therapeutic compounds | |
| TW201613864A (en) | Novel compounds | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine |